US FDA approves Roche’s Evrysdi for use in babies under two months with Spinal Muscular Atrophy
Approval based on interim Rainbowfish data which show pre-symptomatic babies treated with Evrysdi for at least one year were able…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Evrysdi
Evrysdi from ROCHE gets EC nod as home treatment for spinal muscular atrophy
The approval is based on data from two clinical studies, designed to represent a broad spectrum of people living with SMA:…
Roche gets US FDA approval for Evrysdi to treat spinal muscular atrophy
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of…